Company / Capital Expenditures
Krystal Biotech, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$12.0M
FY2025
5-year range
$4.2M / $68.3M
FY2021-FY2025
Trend
+182.0%
vs FY2024
Sector context
#57 of 194
Health Care
What the data says
At $12M, Krystal Biotech, Inc.'s capital expenditures ranks #57 of 194 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 3 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of -4.2%.
Remained stable around $12M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -39.1%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Sector benchmark
#57 of 194 in Health CareTop 29% of 194This company $12.0M Sector average $117.5M
▼
-89.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2025, capital expenditures increased 182.0% year-over-year.
- Ranks #57 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.0M | +182.0% |
| FY2024 | $4.2M | -64.1% |
| FY2023 | $11.8M | -77.7% |
| FY2022 | $53.0M | -22.5% |
| FY2021 | $68.3M | +360.4% |
| FY2020 | $14.8M | +132.0% |
| FY2019 | $6.4M | +186.4% |
| FY2018 | $2.2M | +963.8% |
| FY2017 | $210.0K | +1300.0% |
| FY2016 | $15.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026